Mouse models
|
|
|
|
|
β ARK1 overexpression |
↓aβ AR inotropic response; ↑β ARK1
|
β ARKct |
↑β AR sensitivity; ↓β ARK1 |
(49)
|
bmlp |
DCMc ; β AR desensitization
|
β ARKct |
Prevention of DCM; ↑β AR sensitivity |
(7)
|
CSQd overexpression
|
Cardiomyopathy |
β ARKct ±β -Blocker |
↓ Cardiomyopathy; ↑ survival |
(51)
|
Mutation in MHCe |
HCMf |
β ARKct |
↓ Cardiomyopathy; ↑ exercise tolerance; ↓ hypertrophic gene expression |
(50)
|
CREBA133 expression
|
DCM; ↓ β AR reserve; ↑β ARK1 |
β ARKct |
↑β AR signaling; ↓β ARK1 |
(52)
|
Transverse aortic constriction |
LVg hypertrophy; β AR desensitization; ↑β ARK1
|
CARP–β ARKct |
↑β AR responsiveness |
(55)
|
Isoproterenol (β AR-agonist) |
Myocardial hypertrophy; ↓β ARK1; ↑β AR signaling |
Carvedilol (β -Blocker) |
↑β ARK1; ↓β AR signaling |
(45)
|
Ischemia/reperfusion |
Ischemic myocardial injury |
β ARKct |
↑ Baseline function; ↓ injury |
(54)
|
Non-mouse models
|
|
|
|
|
Sodium deprivation (rat) |
Chronic SNSh activation; ↑β ARK1; ↓β AR signaling (without hypertrophy)
|
β -blocker |
↓β ARK1; ↑β AR signaling |
(47)
|
Induced pacing (rabbit) |
Failing myocytes; ↓β AR density and signaling; ↑β ARK1 |
β ARKct |
↓β ARK1; ↑β AR signaling |
(56)
|
Spontaneous hypertensive heart failure (rat) |
Failing myocytes; ↓β AR signaling; ↓ contractility |
β ARKct |
↑β AR signaling; ↑ contractility |
(57)
|
Myocardial infarction (rabbit) |
↓β AR signaling; ↑β ARK1 |
β ARKct |
↑β AR signaling; ↓β ARK1; ↑ contractility |
(58)
|
Myocardial infarction (rabbit) |
↓β AR signaling; ↓ LV systole |
β ARKct |
↑β AR signaling; ↑ systole |
(59)
|
Pulmonary artery banding (rabbit) |
RVi hypertrophy; death
|
β ARKct |
↑ Survival |
(60)
|
Cardioplegic arrest (rabbit) |
↓ LV function; ↓β AR signaling |
β ARKct |
↑β AR signaling; ↑ cardiac function |
(61)
|
Heterotropic heart transplant (rabbit) |
↓ Cardiac function |
β ARKct |
↑ Cardiac function |
(62)
|